Targeted deletions of complement lectin pathway genes improve outcome in traumatic brain injury, with MASP-2 playing a major role

Targeted deletions of complement lectin pathway genes improve outcome in traumatic brain injury, with MASP-2 playing a major role https://t.co/vTzqfiUJcx https://t.co/IK1L4p8GYD

New from #The_MRC https://t.co/LO0KWT0bZx Targeted deletions of complement lectin pathway genes improve outcome in traumatic brain injury, with MASP-2 playing a major role.

"LP and MASP-2 as novel pharmacological targets for TBI, thus paving the way for future development of clinical strategies. ... Of note, an inhibitory antibody against MASP-2 (Narsoplimab) is currently undergoing phase 3 clinical trials" $omer https://t.c